pexastimogene devacirepvec
AXP000011.2 · Oncolytic virus
- Platform
- vaccinia virus (Wyeth strain, thymidine kinase-deleted)
- Originator
- Jennerex
- Sponsor
- SillaJen
Names
| Name | Type | Source |
|---|---|---|
| pexastimogene devacirepvec | preferred name, INN | curator, ncit |
| JX-594 | code | ncit |
| TG-6006 | code | ncit |
| Pexa-Vec | synonym | ncit |
Virus
- Role
- Oncolytic
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Strain
- Wyeth
- Replication
- conditionally replicating
- Modifications
- J2R (thymidine kinase) disrupted by the transgene cassette
- Transgenes
- CSF2, LacZ
- Route
- intratumoral, intravenous
- Source
- evidence
Cross-references
- NCI Thesaurus
- C71533
- Wikidata
- Q3816624
- FDA UNII
- K82DG47I0G
Approvals
No regulatory approval recorded.
Clinical trials (20)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT04849260 | Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma | Unknown | Phase 1/2 | 2021-08-26 | 2022-05-31 | 54 | Local Progression or Metastatic Melanoma With Failed First-line Treatment |
| NCT03294083 | A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma | Completed | Phase 1/2 | 2018-06-19 | 2023-02-16 | 95 | Renal Cell Carcinoma |
| NCT03206073 | A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer | Completed | Phase 1/2 | 2017-12-07 | 2020-09-24 | 34 | Colorectal Adenocarcinoma; Colorectal Cancer; Colorectal Carcinoma; Colorectal Neoplasms; Refractory Cancer |
| NCT03071094 | A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC) | Terminated | Phase 1/2 | 2017-07-27 | 2020-09-30 | 14 | Hepatocellular Carcinoma (HCC) |
| NCT02977156 | Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. | Completed | Phase 1 | 2017-01-03 | 2022-04-13 | 22 | Advanced Tumor; Metastatic Tumor |
| NCT02562755 | Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone | Completed | Phase 3 | 2015-10 | 2020-07 | 459 | Hepatocellular Carcinoma (HCC) |
| NCT02630368 | A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) | Unknown | Phase 1/2 | 2015-09-18 | 2023-05 | 197 | Breast Cancer; Soft-tissue Sarcoma; Solid Tumors |
| NCT02017678 | Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin | Withdrawn | Phase 2 | 2014-01 | 2015-01 | 0 | Ovarian Cancer |
| NCT01636284 | A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer | Completed | Phase 2 | 2012-06 | 2013-06 | 16 | Hepatocellular Carinoma |
| NCT01394939 | Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma | Completed | Phase 1/2 | 2012-01 | 2015-06 | 52 | CRC; Colorectal Carcinoma |
| NCT01387555 | A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib | Completed | Phase 2 | 2011-10-08 | 2013-10-01 | 129 | HCC; Hepatocellular Carcinoma; Liver Cancer |
| NCT01329809 | Neoadjuvant Recombinant Vaccinia Virus for Metastatic Colorectal Cancer With Liver Resection | Terminated | Phase 2 | 2011-10 | 2012-01 | 2 | Colorectal Carcinoma |
| NCT01380600 | Phase 1b Dose Escalation Study of Intravenous JX-594 in Metastatic, Refractory Colorectal Carcinoma | Completed | Phase 1 | 2010-09-08 | 2012-10-18 | 15 | Carcinoma, Colorectal |
| NCT01169584 | Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients | Completed | Phase 1 | 2010-08 | 2012-03 | 6 | Ewing's Sarcoma; Lymphoma; Neuroblastoma; Rhabdomyosarcoma; Wilm's Tumor |
| NCT01469611 | A Trial of JX-594 in Refractory Colorectal Carcinoma | Completed | Phase 1 | 2010-07 | 2012-10 | 15 | Colorectal Carcinoma |
| NCT01171651 | A Study of Pexa-Vec (JX-594) Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma | Completed | Phase 2 | 2009-05-26 | 2012-09-27 | 25 | Carcinoma, Hepatocellular |
| NCT00554372 | A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma | Completed | Phase 2 | 2008-08 | 2011-12 | 30 | Carcinoma, Hepatocellular |
| NCT00625456 | Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors | Completed | Phase 1 | 2008-06 | 2010-04 | 23 | Lung Cancer; Melanoma; Renal Cell Carcinoma; Squamous Cell Carcinoma of the Head and Neck |
| NCT00429312 | A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma | Completed | Phase 1/2 | 2007-02 | 2008-02 | 10 | Melanoma |
| NCT00629759 | A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma | Completed | Phase 1 | 2006-01 | 2007-07 | 14 | Neoplasms, Liver |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42603198 | Liver Transplantation Following Hepatocellular Carcinoma Rupture and Long-Term Immunotherapy: A Case Report. | Journal of gastrointestinal cancer | 2026 | name in abstract: Pexa-Vec |
| PMID 38378555 | Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide. | Molecular cancer | 2024 | name in title: JX-594 |
| PMID 36754451 | Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer. | Journal for immunotherapy of cancer | 2023 | cited by trial NCT03206073 |
| PMID 36271420 | Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma. | Journal of hematology & oncology | 2022 | name in title: JX-594 |
| PMID 31413923 | Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). | Oncoimmunology | 2019 | cited by trial NCT01387555 |
| PMID 25531693 | Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. | Molecular therapy : the journal of the American Society of Gene Therapy | 2015 | name in title: Pexa-Vec |
| PMID 26072416 | A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma. | Methods in molecular biology (Clifton, N.J.) | 2015 | name in title: Pexa-Vec |
| PMID 26073886 | Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer. | Molecular therapy : the journal of the American Society of Gene Therapy | 2015 | name in title: Pexa-Vec |
| PMID 26471278 | Isolation of vaccinia JX594 from pustules following therapy for hepatocellular carcinoma. | BMC cancer | 2015 | name in title: JX-594 |
| PMID 23393196 | Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. | Cancer research | 2013 | cited by trial NCT00554372 |
| PMID 23396206 | Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. | Nature medicine | 2013 | cited by trial NCT00554372 |
| PMID 23677592 | Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. | Science translational medicine | 2013 | name in abstract: pexastimogene devacirepvec |
| PMID 21772252 | A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. | Molecular therapy : the journal of the American Society of Gene Therapy | 2011 | name in title: JX-594 |
| PMID 18495536 | Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. | The Lancet. Oncology | 2008 | cited by trial NCT00629759 |
Unconfirmed matches (2)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 37384323 | Early Experience of Oncolytic Virus Injection Combined with Sorafenib in a Patient with Advanced Hepatocellular Carcinoma and Portal Vein Thrombosis. | Journal of liver cancer | 2020 | name in abstract: JX-594 |
| PMID 21886163 | Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. | Nature | 2011 | name in abstract: JX-594 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42156493 | Oncolytic vaccinia virus JX-594 shows subtype-specific activity and candidate biomarkers in gastric cancer cell lines. | Scientific reports | 2026 | name in title: JX-594 |
| PMID 42456895 | Oncolytic viruses in cancer therapy: Mechanisms, challenges, and emerging clinical applications. | Annales pharmaceutiques francaises | 2026 | name in abstract: Pexa-Vec |
| PMID 42636898 | Killing to cure: harnessing poxvirus-driven cell death for viral immunotherapy. | Immunology letters | 2026 | name in abstract: pexastimogene devacirepvec |
| PMID 42837725 | Oncolytic viruses in gastrointestinal malignancies: Clinical progress, translational challenges, and future directions. | Seminars in oncology | 2026 | name in abstract: pexastimogene devacirepvec |
| PMID 42909267 | Liver-resident cellular determinants of oncolytic virotherapy in hepatocellular carcinoma: viral susceptibility and spatial immune remodeling. | Frontiers in cell and developmental biology | 2026 | name in abstract: Pexa-Vec |
| PMID 41228258 | The Emerging Role of Oncolytic Virotherapy in Glioblastoma Management. | Cancers | 2025 | name in abstract: Pexa-Vec |
| PMID 38756145 | PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma. | Liver cancer | 2024 | name in title: Pexa-Vec |
| PMID 38837373 | Gene therapy for people with hepatocellular carcinoma. | The Cochrane database of systematic reviews | 2024 | name in abstract: pexastimogene devacirepvec |
| PMID 36717184 | Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies. | Journal for immunotherapy of cancer | 2023 | name in abstract: Pexa-Vec |
| PMID 36896445 | Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions. | Asian journal of pharmaceutical sciences | 2023 | name in abstract: pexastimogene devacirepvec |
| PMID 35052851 | Systemic Injection of Oncolytic Vaccinia Virus Suppresses Primary Tumor Growth and Lung Metastasis in Metastatic Renal Cell Carcinoma by Remodeling Tumor Microenvironment. | Biomedicines | 2022 | name in abstract: pexastimogene devacirepvec |
| PMID 35118189 | Oncolytic vaccinia virus injected intravenously sensitizes pancreatic neuroendocrine tumors and metastases to immune checkpoint blockade. | Molecular therapy oncolytics | 2022 | name in abstract: Pexa-Vec |
| PMID 35439304 | Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients. | Cancer immunology research | 2022 | name in abstract: pexastimogene devacirepvec |
| PMID 35453555 | Oncolytic Vaccinia Virus Augments T Cell Factor 1-Positive Stem-like CD8+ T Cells, Which Underlies the Efficacy of Anti-PD-1 Combination Immunotherapy. | Biomedicines | 2022 | name in abstract: pexastimogene devacirepvec |
| PMID 35565310 | Intravenous Oncolytic Vaccinia Virus Therapy Results in a Differential Immune Response between Cancer Patients. | Cancers | 2022 | name in abstract: Pexa-Vec |
| PMID 36467495 | Progress of oncolytic virotherapy for neuroblastoma. | Frontiers in pediatrics | 2022 | name in abstract: Pexa-Vec |
| PMID 36474303 | Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer. | Experimental hematology & oncology | 2022 | name in title: JX-594 |
| PMID 34332591 | Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis. | Virology journal | 2021 | name in abstract: pexastimogene devacirepvec |
| PMID 35116288 | The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis. | Translational cancer research | 2021 | name in abstract: Pexa-Vec |
| PMID 32162802 | Intratumoral Immunotherapy-Update 2019. | The oncologist | 2020 | name in abstract: Pexa-Vec |
| PMID 32690442 | Kinase inhibitors with viral oncolysis: Unmasking pharmacoviral approaches for cancer therapy. | Cytokine & growth factor reviews | 2020 | name in abstract: Pexa-Vec |
| PMID 30462296 | Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives. | Japanese journal of clinical oncology | 2019 | name in abstract: pexastimogene devacirepvec |
| PMID 30626434 | Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. | Journal for immunotherapy of cancer | 2019 | name in abstract: Pexa-Vec |
| PMID 31428674 | Deletion of Apoptosis Inhibitor F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer Therapy. | Molecular therapy oncolytics | 2019 | name in abstract: Pexa-Vec |
| PMID 28359239 | Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers. | Current cancer drug targets | 2018 | name in abstract: pexastimogene devacirepvec |
| PMID 27635026 | Enhancing Expression of Functional Human Sodium Iodide Symporter and Somatostatin Receptor in Recombinant Oncolytic Vaccinia Virus for In Vivo Imaging of Tumors. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2017 | name in abstract: Pexa-Vec |
| PMID 27901484 | Gene expression profiling of hematologic malignant cell lines resistant to oncolytic virus treatment. | Oncotarget | 2017 | name in abstract: Pexa-Vec |
| PMID 27451890 | Vacca pox to pexa vec: John Hunter's and Edward Jenner's contribution to oncolytic virotherapy. | The Journal of surgical research | 2016 | name in title: Pexa-Vec |
| PMID 27486853 | Oncolytic virus therapy: A new era of cancer treatment at dawn. | Cancer science | 2016 | name in abstract: pexastimogene devacirepvec |
| PMID 25807289 | Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques. | Molecular therapy : the journal of the American Society of Gene Therapy | 2015 | name in abstract: Pexa-Vec |
| PMID 25900822 | Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic. | Current opinion in virology | 2015 | name in title: Pexa-Vec |
| PMID 27512667 | The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594). | Oncolytic virotherapy | 2015 | name in title: Pexa-Vec |
| PMID 23836532 | New frontier in liver cancer treatment: oncolytic viral therapy. | Hepatology (Baltimore, Md.) | 2014 | name in abstract: Pexa-Vec |
| PMID 24020520 | Oncolytic viruses as therapeutic cancer vaccines. | Molecular cancer | 2013 | name in abstract: Pexa-Vec |
| PMID 21740365 | Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594. | Current pharmaceutical biotechnology | 2012 | name in title: JX-594 |
| PMID 22186794 | The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. | Molecular therapy : the journal of the American Society of Gene Therapy | 2012 | name in title: JX-594 |
| PMID 21427706 | Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. | Molecular therapy : the journal of the American Society of Gene Therapy | 2011 | name in title: JX-594 |
| PMID 20808290 | Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma. | Molecular therapy : the journal of the American Society of Gene Therapy | 2010 | name in title: JX-594 |
| PMID 19943208 | JX-594, a targeted oncolytic poxvirus for the treatment of cancer. | Current opinion in investigational drugs (London, England : 2000) | 2009 | name in title: JX-594 |
| PMID 18628758 | The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. | Molecular therapy : the journal of the American Society of Gene Therapy | 2008 | name in title: JX-594 |
| PMID 16905462 | Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. | Molecular therapy : the journal of the American Society of Gene Therapy | 2006 | name in title: JX-594 |
Unconfirmed matches (20)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40685482 | Oncolytic virotherapy and tumor microenvironment modulation. | Clinical and experimental medicine | 2025 | name in abstract: JX-594 |
| PMID 40856833 | BAP1 as a predictive biomarker of therapeutic response to oncolytic vaccinia virus for metastatic renal cell carcinoma therapy. | Cancer immunology, immunotherapy : CII | 2025 | name in abstract: JX-594 |
| PMID 41662640 | Review Article: Intratumoral Immunotherapy: Old Discoveries and Recent Developments in Sarcomas. | Critical reviews in oncogenesis | 2025 | name in abstract: JX-594 |
| PMID 38291394 | PD-1 inhibitor plus oncolytic vaccinia virus is a safe and effective treatment option for metastatic renal cell carcinoma. | Cancer cell international | 2024 | name in abstract: JX-594 |
| PMID 39598813 | Using Computer Modeling and Experimental Methods to Screen for Aptamers That Bind to the VV-GMCSF-LACT Virus. | Molecules (Basel, Switzerland) | 2024 | name in abstract: JX-594 |
| PMID 37749907 | Oncolytic virotherapies for pediatric tumors. | Expert opinion on biological therapy | 2023 | name in abstract: JX-594 |
| PMID 29259007 | Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms. | Cancer research | 2018 | name in abstract: JX-594 |
| PMID 29900755 | Exploring the role of oncolytic viruses in hepatobiliary cancers. | Immunotherapy | 2018 | name in abstract: JX-594 |
| PMID 28496337 | Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes. | OncoTargets and therapy | 2017 | name in abstract: JX-594 |
| PMID 26803055 | Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9. | Cancer letters | 2016 | name in abstract: JX-594 |
| PMID 25711964 | Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma. | The Journal of general virology | 2015 | name in abstract: JX-594 |
| PMID 24502935 | Viral warfare! Front-line defence and arming the immune system against cancer using oncolytic vaccinia and other viruses. | The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland | 2014 | name in abstract: JX-594 |
| PMID 23433318 | Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics. | Orphanet journal of rare diseases | 2013 | name in abstract: JX-594 |
| PMID 23824333 | Live viruses to treat cancer. | Journal of the Royal Society of Medicine | 2013 | name in abstract: JX-594 |
| PMID 21338330 | Oncolytic vaccinia virus for the treatment of cancer. | Expert opinion on biological therapy | 2011 | name in abstract: JX-594 |
| PMID 22102388 | Effect of aldosterone on the amplification of oncolytic vaccinia virus in human cancer lines. | The Korean journal of hepatology | 2011 | name in abstract: JX-594 |
| PMID 20472490 | Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. | Cytokine & growth factor reviews | 2010 | name in abstract: JX-594 |
| PMID 20852754 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2010 | name in abstract: JX-594 |
| PMID 19798455 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2009 | name in abstract: JX-594 |
| PMID 18850047 | Gateways to clinical trials. July-August 2008. | Methods and findings in experimental and clinical pharmacology | 2008 | name in abstract: JX-594 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| ZIABC011343 | Clinical protocols for the treatment of gastrointestinal cancer | DIVISION OF BASIC SCIENCES - NCI | GRETEN, TIM | 2019–2023 | name in abstract: Pexa-Vec |
| DP2CA195764 | Oncolytic Virotherapy in Hepatocellular Cancer | MAYO CLINIC ARIZONA | BORAD, MITESH | 2014–2016 | name in abstract: Pexa-Vec |
Notes
Jennerex acquired by SillaJen in 2014; Transgene was a partner and used the code TG-6006. Not the same product as TG6002, a different Transgene vaccinia construct. Transgenes moved from targets to virus.tsv (spec 0.2).
How to cite
pexastimogene devacirepvec (AXP000011.2). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000011.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.